MX352459B - Composiciones de eter-sulfoalquilico-ciclodextrina. - Google Patents

Composiciones de eter-sulfoalquilico-ciclodextrina.

Info

Publication number
MX352459B
MX352459B MX2013005803A MX2013005803A MX352459B MX 352459 B MX352459 B MX 352459B MX 2013005803 A MX2013005803 A MX 2013005803A MX 2013005803 A MX2013005803 A MX 2013005803A MX 352459 B MX352459 B MX 352459B
Authority
MX
Mexico
Prior art keywords
sae
sulfoalkyl ether
ether cyclodextrin
cyclodextrin compositions
composition
Prior art date
Application number
MX2013005803A
Other languages
English (en)
Inventor
Vincent Antle
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41215591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352459(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of MX352459B publication Critical patent/MX352459B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones de SAE-CD, junto con métodos para elaborar y utilizar las mismas. La composición de SAE-CD comprende una éter sulfoalquílico-ciclodextrina y menos de 100 ppm de un fosfato, en donde la composición de SAE-CD tiene una absorción menor que 0.5 A.U. debido a un agente degradante de fármaco, determinada mediante la espectrofotometría de UV/vis en una longitud de onda de 245 nm a 270 nm para una solución acuosa que contiene 300 mg de la composición de SAE-CD por mL de solución en una celda que tiene una longitud de trayectoria de 1 cm.
MX2013005803A 2008-04-28 2009-04-28 Composiciones de eter-sulfoalquilico-ciclodextrina. MX352459B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4851808P 2008-04-28 2008-04-28
US12/404,174 US7635773B2 (en) 2008-04-28 2009-03-13 Sulfoalkyl ether cyclodextrin compositions
PCT/US2009/002572 WO2009134347A2 (en) 2008-04-28 2009-04-28 Sulfoalkyl ether cyclodextrin compositions

Publications (1)

Publication Number Publication Date
MX352459B true MX352459B (es) 2017-11-27

Family

ID=41215591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005803A MX352459B (es) 2008-04-28 2009-04-28 Composiciones de eter-sulfoalquilico-ciclodextrina.
MX2010004900A MX2010004900A (es) 2008-04-28 2009-04-28 Composiciones de eter-sulfoalquilico-ciclodextrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010004900A MX2010004900A (es) 2008-04-28 2009-04-28 Composiciones de eter-sulfoalquilico-ciclodextrina.

Country Status (14)

Country Link
US (7) US7635773B2 (es)
EP (2) EP3363430A1 (es)
JP (5) JP4923144B2 (es)
KR (1) KR101314803B1 (es)
CN (3) CN101959508A (es)
AU (1) AU2009241858B2 (es)
BR (1) BRPI0905080B8 (es)
CA (2) CA2702603C (es)
EA (1) EA031355B1 (es)
HK (1) HK1219883A1 (es)
IL (2) IL208956A (es)
MX (2) MX352459B (es)
NZ (1) NZ589290A (es)
WO (1) WO2009134347A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2335707T3 (pl) * 2005-10-26 2015-10-30 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EP2429291B1 (en) 2009-05-13 2016-07-06 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
NZ596515A (en) 2009-05-29 2014-03-28 Cydex Pharmaceuticals Inc Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CA2802929C (en) 2010-06-29 2019-01-08 David Monteith Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
PL2616064T3 (pl) 2010-10-21 2020-02-28 Rtu Pharmaceuticals Llc Gotowe do zastosowania formulacje ketorolaku
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания
CA2831213C (en) * 2011-03-27 2016-05-17 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
RU2747757C2 (ru) 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
JP6193970B2 (ja) 2012-03-30 2017-09-06 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対するデルフィニジンの使用
KR101905937B1 (ko) 2012-03-30 2018-10-08 자피오텍 게엠베하 안토시아니딘 복합체
KR20220088949A (ko) 2012-05-08 2022-06-28 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
CN102718891A (zh) * 2012-06-04 2012-10-10 咸阳西秦生物科技有限公司 利用膜分离与溶剂沉淀纯化制备磺丁基醚-β-环糊精的方法
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
JP2015534970A (ja) * 2012-10-17 2015-12-07 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 多発性骨髄腫の治療のためのアントシアニジン複合体
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CN102993338B (zh) * 2012-12-04 2015-06-10 陕西科技大学 磺丁基-α-环糊精及其制备方法
CA2893883A1 (en) * 2012-12-11 2014-06-19 Sapiotec Gmbh Delphinidin for combating melanoma cells
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103694376B (zh) * 2014-01-10 2016-04-13 凯莱英医药集团（天津）股份有限公司 一种制备磺丁基醚-β-环糊精的方法
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP2913366A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex
US10662260B2 (en) 2014-05-29 2020-05-26 Uti Limited Partnership Cyclodextrin-based polyanionic and non-ionic dendrimers
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
CN104874422B (zh) * 2015-04-02 2017-07-21 安徽师范大学 吡啶‑金刚烷胺配合物/β‑环糊精包合物及其制备方法和应用
WO2016195476A1 (en) 2015-05-29 2016-12-08 Erasmus University Medical Center Rotterdam Treatment of cardiac arrhythmias
US20170007617A1 (en) 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
CN104974275A (zh) * 2015-07-30 2015-10-14 淄博千汇生物科技有限公司 磺烷基醚环糊精衍生物的合成方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
SG11201809908TA (en) * 2016-05-09 2018-12-28 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
WO2018146698A1 (en) * 2017-02-07 2018-08-16 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
CN108034011A (zh) * 2017-12-28 2018-05-15 山东滨州智源生物科技有限公司 一种绿色高效环糊精衍生物生产精制工艺
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN110575826A (zh) * 2019-09-16 2019-12-17 天津科技大学 一种磺酸基环糊精衍生物及其修饰的纳米二氧化钛的制备方法
CN113151246B (zh) * 2021-02-18 2022-06-21 杭州楠大环保科技有限公司 易腐垃圾降解菌剂及其应用
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
CN115505052B (zh) * 2022-08-23 2023-05-23 安徽普利药业有限公司 一种β-环糊精衍生物的制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2744938A (en) 1952-07-24 1956-05-08 Universal Oil Prod Co Removal of color impurities from organic compounds
US3033900A (en) 1958-03-25 1962-05-08 Pfanstiehl Lab Inc Method of preparing calcium glucoheptonate
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
CA978308A (en) 1971-09-09 1975-11-25 Scott Paper Company Use of activated carbon to recover and separate chemicals produced during pulping operations
US4292176A (en) 1976-12-08 1981-09-29 Standard Oil Company (Indiana) Use of activated carbon in waste water treating process
JPS5953038B2 (ja) 1979-04-07 1984-12-22 メルシャン株式会社 サイクロデキストリンの製造法
NL8104410A (nl) 1981-09-24 1983-04-18 Proefstation Voor Aardappelver Werkwijze ter bereiding van cyclodextrine.
JPS5862152A (ja) 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
US4818411A (en) 1983-12-16 1989-04-04 Ecolochem, Inc. Deoxygenation process
HU194939B (en) 1983-12-22 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing alpha- beta- and gamma cyclodextrine of high yield capacity
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61169149A (ja) 1985-01-22 1986-07-30 Nippon Mining Co Ltd 連続鋳造方法
US4597946A (en) 1985-04-30 1986-07-01 Uop Inc. Vertical tube reactor with serial downward flow through a plurality of sets of particulate containing tubes
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US4738923A (en) * 1986-05-20 1988-04-19 American Maize-Products Company Process for producing and separating cyclodextrins
EP0274259B1 (en) 1986-12-19 1994-02-16 Sankyo Company Limited New renin-inhibitory oligopeptides, their preparaton and their use
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5019562A (en) 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5183809A (en) 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US4904306A (en) 1988-07-22 1990-02-27 American Maize-Products Company Separation and purification of gamma cyclodextrin
US5007967A (en) 1988-08-15 1991-04-16 American Maize-Products Company Separation and purification of branched beta cyclodextrins
ATE166884T1 (de) 1989-04-03 1998-06-15 Janssen Pharmaceutica Nv Regioselektive substitutionen von cyclodextrinen
US5173481A (en) 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1991018022A1 (fr) 1990-05-21 1991-11-28 Toppan Printing Co., Ltd. Derive de cyclodextrine
JP2905573B2 (ja) 1990-06-28 1999-06-14 日本食品化工株式会社 ヒドロキシアルキル化シクロデキストリン精製物及びその製造法
FR2668163B1 (fr) 1990-10-18 1993-01-15 Orsan Procede de fabrication de beta-cyclodextrine.
JPH051102A (ja) 1991-05-29 1993-01-08 Toppan Printing Co Ltd シクロデキストリン誘導体
CN1072185A (zh) * 1991-11-13 1993-05-19 美国玉米产品公司 制备非混浊型环糊精的方法
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE69322721T2 (de) 1992-09-24 1999-06-10 Terumo Corp Sulfonierte Verbindungen aus Beta-Cyclodextrinpolymer und diese enthaltendes Medikament welches die Hyperplasie von Gefässwanden hemmt
FR2705963B1 (fr) 1993-06-03 1995-07-13 Commissariat Energie Atomique Dérivés sulfonés de cyclomalto-oligosaccharides, leur procédé de préparation et support de substances actives contenant ces dérivés.
US5393880A (en) * 1993-06-17 1995-02-28 American Maize-Products Company Cyclodextrin refining process
US5568756A (en) * 1993-08-31 1996-10-29 Peterson; Carl J. Support means for a saw machine
DE4333598A1 (de) 1993-10-01 1995-04-06 Consortium Elektrochem Ind Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
US5479254A (en) 1993-10-22 1995-12-26 Woskov; Paul P. Continuous, real time microwave plasma element sensor
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
DE4401618A1 (de) 1994-01-20 1995-07-27 Consortium Elektrochem Ind Verfahren zur Herstellung von aminofunktionellen Cyclodextrin Derivaten
US5494869A (en) 1994-03-29 1996-02-27 Calgon Carbon Corporation Process for regenerating nitrogen-treated carbonaceous chars used for hydrogen sulfide removal
US5658390A (en) 1994-06-29 1997-08-19 American Maize-Products Company Purification of beta cyclodextrin
DE4428654A1 (de) 1994-08-12 1996-02-15 Consortium Elektrochem Ind Wasserlösliche Cyclodextrinderivate mit lipophilen Substituenten und Verfahren zu ihrer Herstellung
US5550222A (en) 1994-12-14 1996-08-27 American Maize-Products Company Process for producing gamma-cyclodextrin
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US5569756A (en) * 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US6057262A (en) 1995-05-19 2000-05-02 University Of Kentucky Research Foundation Activated carbon and process for making same
US5614459A (en) 1995-06-07 1997-03-25 Universidad De Antioquia Process for making activated charcoal
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) * 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6033573A (en) * 1997-05-29 2000-03-07 The United States Of America As Represented By The Secretary Of Agriculture Activated nutshell carbons from agricultural waste
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
ES2264211T3 (es) 1997-08-26 2006-12-16 Board Of Regents, The University Of Texas System Uso de una composicion que comprende un agente quelante y un compuesto antimicrobiano para el tratamiento de biopeliculas.
US6165484A (en) 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6391862B1 (en) 1997-10-14 2002-05-21 The Texas A&M University System Chiral resolving agents for enantioseparations
WO1999027932A1 (en) 1997-12-01 1999-06-10 Schering Corporation Injectable antifungal formulations
AU759280C (en) 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
TW394749B (en) * 1998-03-05 2000-06-21 Deng Jian Lang Method of manufacturing active carbon by using carbon black
AT410321B (de) 1998-08-11 2003-03-25 Tulln Zuckerforschung Gmbh Verfahren zur herstellung von cyclodextrin
DE19983660T1 (de) 1998-10-20 2001-09-13 Ben Venue Lab Inc Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
DE19930553A1 (de) 1999-07-02 2001-01-11 Wacker Chemie Gmbh Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten
WO2001001955A1 (en) 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
FR2808691B1 (fr) 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
US7709415B2 (en) 2002-04-22 2010-05-04 Kuraray Chemical Co., Ltd. Method for manufacturing activated carbon, polarizable electrode, and electric double-layered capacitor
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6709746B2 (en) 2002-06-05 2004-03-23 Arteva North America S.á.r.l. Reducing concentration of organic materials with substituted cyclodextrin compound in polyester packaging materials
ES2322953T3 (es) 2002-08-20 2009-07-02 Bristol-Myers Squibb Company Formulacion del complejo de aripiprazol y procedimiento.
AU2003275329B2 (en) 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
EA008438B1 (ru) 2003-01-14 2007-06-29 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептида для лечения системной красной волчанки
EA009123B1 (ru) 2003-01-14 2007-10-26 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептидов для лечения системной красной волчанки
ES2322464T3 (es) 2003-02-27 2009-06-22 Glaxo Group Limited Composicion de fondaparinux sodico de alta pureza.
CN100482338C (zh) 2003-10-10 2009-04-29 帝斯曼知识产权资产管理有限公司 活性碳处理
EP1678211A4 (en) * 2003-10-31 2008-04-02 Univ Kansas SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRINS DERIVATIVES
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
US20050250738A1 (en) 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
JP5108509B2 (ja) 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
US7559241B2 (en) 2004-05-27 2009-07-14 Sulphco, Inc. High-throughput continuous-flow ultrasound reactor
US20060009469A1 (en) 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
EP1753762B1 (en) 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060079720A1 (en) 2004-10-13 2006-04-13 Milliken & Company Method for preparing acetal-containing compositions
PT2261236E (pt) 2004-12-07 2015-10-30 Onyx Therapeutics Inc Composição para a inibição de proteassoma
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007037508A1 (en) 2005-09-29 2007-04-05 Showa Denko K.K. Activated carbon and process of making the same
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2335707T3 (pl) * 2005-10-26 2015-10-30 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
ES2532084T3 (es) 2006-09-15 2015-03-24 Regents Of The University Of Minnesota Composiciones de topiramato y métodos para su uso
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
EP2018866A1 (en) 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20160086980A (ko) 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
AU2008317315A1 (en) 2007-10-26 2009-04-30 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
AU2009236290A1 (en) 2008-04-15 2009-10-22 Merck Sharp & Dohme Corp. Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
JP5274878B2 (ja) 2008-04-15 2013-08-28 パナソニック株式会社 半導体装置及びその製造方法
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EP2429291B1 (en) 2009-05-13 2016-07-06 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
NZ596515A (en) 2009-05-29 2014-03-28 Cydex Pharmaceuticals Inc Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
CA2802929C (en) 2010-06-29 2019-01-08 David Monteith Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
CN102040675B (zh) 2010-12-22 2012-10-03 石药集团中诺药业（石家庄）有限公司 一种羟丙基-β-环糊精的制备方法
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
RU2747757C2 (ru) 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
AR087863A1 (es) 2012-05-08 2014-04-23 Onyx Therapeutics Inc Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
WO2014066274A1 (en) * 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
CN104892797B (zh) 2015-05-28 2017-03-22 天津大学 特定平均取代度磺丁基醚‑β‑环糊精的合成方法
CN104974275A (zh) 2015-07-30 2015-10-14 淄博千汇生物科技有限公司 磺烷基醚环糊精衍生物的合成方法

Also Published As

Publication number Publication date
NZ589290A (en) 2012-12-21
US20160346405A1 (en) 2016-12-01
US9750822B2 (en) 2017-09-05
JP4923144B2 (ja) 2012-04-25
HK1219883A1 (zh) 2017-04-21
US20190070303A1 (en) 2019-03-07
JP2015110671A (ja) 2015-06-18
US20160158384A1 (en) 2016-06-09
KR101314803B1 (ko) 2013-10-10
MX2010004900A (es) 2010-06-07
EP3363430A1 (en) 2018-08-22
IL243654A0 (en) 2016-02-29
JP2017019879A (ja) 2017-01-26
BRPI0905080B1 (pt) 2019-04-30
AU2009241858B2 (en) 2015-09-17
CA2771879A1 (en) 2009-11-05
IL243654B (en) 2019-07-31
EP2268269A2 (en) 2011-01-05
US20210093727A1 (en) 2021-04-01
US7635773B2 (en) 2009-12-22
CN114053423A (zh) 2022-02-18
CA2702603A1 (en) 2009-11-05
BRPI0905080A2 (pt) 2015-06-30
EA031355B1 (ru) 2018-12-28
CA2702603C (en) 2012-06-19
JP2012072160A (ja) 2012-04-12
JP6276828B2 (ja) 2018-02-07
JP2010539193A (ja) 2010-12-16
CN101959508A (zh) 2011-01-26
BRPI0905080B8 (pt) 2021-05-25
WO2009134347A2 (en) 2009-11-05
IL208956A0 (en) 2011-01-31
IL208956A (en) 2016-02-29
US10117951B2 (en) 2018-11-06
US20130184357A1 (en) 2013-07-18
US20090270348A1 (en) 2009-10-29
KR20110010742A (ko) 2011-02-07
AU2009241858A1 (en) 2009-11-05
US9200088B2 (en) 2015-12-01
JP2018052991A (ja) 2018-04-05
CN105288650A (zh) 2016-02-03
US10780177B2 (en) 2020-09-22
JP6039721B2 (ja) 2016-12-07
JP6444548B2 (ja) 2018-12-26
EA201000828A1 (ru) 2011-10-31
EP2268269A4 (en) 2011-08-17
WO2009134347A3 (en) 2010-01-14
US11806402B2 (en) 2023-11-07
US8410077B2 (en) 2013-04-02
US20100093663A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MX352459B (es) Composiciones de eter-sulfoalquilico-ciclodextrina.
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
RS51185B (sr) Kompozicije za vaginalnu primenu
MX2007008457A (es) Eter n, n, n'-trimetil-bis-(aminoetilico) y sus derivados como catalizadores para poliuretanos.
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010011284A3 (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
PL1933809T3 (pl) Kompozycje do dostarczania donosowego
WO2014194195A3 (en) Cyclodextrin-based polymers for the therapeutic delivery
WO2006078659A3 (en) Stable prostaglandin-containing compositions
TW200700092A (en) Tigecycline compositions and methods of preparation
WO2013016668A3 (en) Methylphenidate-prodrugs, processes of making and using the same
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
WO2009098716A3 (en) Stabilized aqueous formulation containing paracetamol
MX2013012151A (es) Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.
WO2013055417A3 (en) Thiophene based oligomers as light activated biocides
MY153899A (en) Compositions containing sesamin-class compound(s) and quercetin glycoside(s)
GB0706335D0 (en) Porphyrin compounds
GT201000235A (es) Un producto para incrementar la fotosintesis
MX2009009533A (es) Conjugados de hidroxipolimero modificado con efecto letal en celulas tumorales.
CL2009000453A1 (es) Composicion farmaceutica que comprende i) compuesto derivado triciclico nitrogenado, tal como pirido[2,3-b]indol, ii) al menos un derivado de ciclodextrina y iii) agua, util para prevenir o tratar cancer e inflamacion, entre otras; metodo para mejorar la solubilidad y estabilidad en agua de dichos compuestos.
MX347677B (es) Formulacion farmaceutica entre jasmonatos y sus derivados y nanoportadores o microportadores.
PE20091098A1 (es) Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina
WO2010056452A3 (en) Dimeric cyanoacrylate compounds as red-shifted uv absorbers
WO2007117432A3 (en) Methods and compositions for modulating angiogenesis and tumor growth